Trans-sialidases obtained from Trypanosoma congolense
    1.
    发明授权
    Trans-sialidases obtained from Trypanosoma congolense 失效
    来自锥虫的转唾液酸酶

    公开(公告)号:US07655784B2

    公开(公告)日:2010-02-02

    申请号:US10538840

    申请日:2003-12-11

    IPC分类号: C07H21/02 C07H21/04 A61K39/00

    CPC分类号: C12N9/1081

    摘要: The invention relates to novel enzymes, which transfer sialic acid from a donor molecule onto an acceptor molecule (trans-sialidases). The enzymes are isolated from the protozoan Trypanosoma congolense. The invention also relates to functional equivalents of said enzymes, to the nucleic acid sequences and amino acid sequences that code for the enzymes and their functional equivalents, to expression constructs and vectors that contain said sequences, to recombinant microorganisms that carry the inventive coding nucleic-acid sequences, to a method for the recombinant production of the inventive enzymes, to a method for isolating said enzyme from Trypanosoma congolense, to a method for the enzymatic sialization of acceptor molecules using the inventive enzymes, to effectors of the inventive trans-sialidases, to the use of the nucleic acid sequences, amino acid sequences, enzymes, effectors or sialization products for producing vaccines, medicaments, foodstuffs or food additives, in addition to the latter products obtained by the inventive method.

    摘要翻译: 本发明涉及将唾液酸从供体分子转移到受体分子(反唾液酸酶)上的新型酶。 这些酶是从原生动物锥虫中分离的。 本发明还涉及所述酶的功能等同物,编码酶及其功能等同物的核酸序列和氨基酸序列,含有所述序列的表达构建体和载体,携带本发明编码核酸的重组微生物, 酸序列,重组生产本发明酶的方法,用于将所述酶与锥虫属分离的方法,使用本发明酶将受体分子酶促唾液酸化的方法用于本发明的反唾液酸酶的实施者, 使用除了通过本发明方法获得的后一种产品之外的核酸序列,氨基酸序列,酶,效应物或用于生产疫苗,药物,食品或食品添加剂的唾液化产品。

    Trans-sialidases obtained from trypanosoma congolense
    2.
    发明申请
    Trans-sialidases obtained from trypanosoma congolense 失效
    从锥虫congolense获得的反唾液酸酶

    公开(公告)号:US20070004656A1

    公开(公告)日:2007-01-04

    申请号:US10538840

    申请日:2003-12-11

    CPC分类号: C12N9/1081

    摘要: The invention relates to novel enzymes, which transfer sialic acid from a donor molecule onto an acceptor molecule (trans-sialidases). The enzymes are isolated from the protozoan Trypanosoma congolense. The invention also relates to functional equivalents of said enzymes, to the nucleic acid sequences and amino acid sequences that code for the enzymes and their functional equivalents, to expression constructs and vectors that contain said sequences, to recombinant microorganisms that carry the inventive coding nucleic-acid sequences, to a method for the recombinant production of the inventive enzymes, to a method for isolating said enzyme from Trypanosoma congolense, to a method for the enzymatic sialization of acceptor molecules using the inventive enzymes, to effectors of the inventive trans-sialidases, to the use of the nucleic acid sequences, amino acid sequences, enzymes, effectors or sialization products for producing vaccines, medicaments, foodstuffs or food additives, in addition to the latter products obtained by the inventive method.

    摘要翻译: 本发明涉及将唾液酸从供体分子转移到受体分子(反唾液酸酶)上的新型酶。 这些酶是从原生动物锥虫中分离的。 本发明还涉及所述酶的功能等同物,编码酶及其功能等同物的核酸序列和氨基酸序列,含有所述序列的表达构建体和载体,携带本发明编码核酸的重组微生物, 酸序列,重组生产本发明酶的方法,用于将所述酶与锥虫属分离的方法,使用本发明酶将受体分子酶促唾液酸化的方法用于本发明的反唾液酸酶的实施者, 使用除了通过本发明方法获得的后一种产品之外的核酸序列,氨基酸序列,酶,效应物或用于生产疫苗,药物,食品或食品添加剂的唾液化产品。

    Anti-infectious carbohydrates
    6.
    发明授权
    Anti-infectious carbohydrates 失效
    抗感染性碳水化合物

    公开(公告)号:US07858595B2

    公开(公告)日:2010-12-28

    申请号:US10490102

    申请日:2002-09-25

    CPC分类号: A61K31/702 A61K31/715

    摘要: Neutral straight-chain or branched oligosaccharides for preventing the invasion and infection of mammal cells by pathogens and for fighting diseases caused by such pathogens are disclosed. Food, dietetic products and pharmaceutical agents containing oligosaccharides consist of a base unit of formula (I), and between 0 and 19 other units of formula (II), which are linked directly or indirectly to the base unit. Gal represents a galactose monosaccharide unit; Glc represents a glucose monosaccharide unit; HexNAc rpresents an N-acetylated galactosamine or glucosamine monosaccharide unit (GalNAc or GlcNAc); R independently represent a β 1-3 or β 1-6 glycosidic link to HexNAc monosaccharide of the next [Gal-HexNAc] unit (II), and on a terminal [Gal-HexNAc] unit, or R are not present; and a terminal [Gal-HexNAc] unit, wherein R represent a deoxyhexose radical, can have another deoxyhexose radical on the HexNAc monosaccharide unit.

    摘要翻译: 公开了用于防止病原体侵染和感染哺乳动物细胞并用于与这种病原体引起的疾病的中性直链或支链寡糖。 含有寡糖的食品,饮食产品和药剂由式(I)的基本单元和0至19个式(II)的其它单元直接或间接连接到基础单元组成。 Gal代表半乳糖单糖单位; Glc表示葡萄糖单糖单元; HexNAc表示N-乙酰化的半乳糖胺或葡糖胺单糖单元(GalNAc或GlcNAc); R独立地代表一个 1-3或&bgr; 1-6糖苷键连接到下一个[Gal-HexNAc]单元(II)的HexNAc单糖和末端[Gal-HexNAc]单元或R不存在; 和末端[Gal-HexNAc]单元,其中R表示脱氧己糖基团,可以在HexNAc单糖单元上具有另一脱氧己糖基团。

    Sialic carbohydrates
    8.
    发明申请
    Sialic carbohydrates 审中-公开
    唾液碳水化合物

    公开(公告)号:US20050070464A1

    公开(公告)日:2005-03-31

    申请号:US10502049

    申请日:2003-01-31

    摘要: The invention relates to the use of sialic carbohydrates of general formula (I), containing at least one carbohydrate unit of general formula (II) for the immune modulation, immune suppression and in the prevention and treatment of infections in humans and animals. In said formula (II), Sia represents a sialic acid or a sialic acid derivative in an α2-3 bond, Gal represents a galactose-monosaccharide-unit, HexNac represents an N-acetylated galactosamine or glucosamine-monosaccharide-unit (GalNAc or GlcNAc), Hex represents a galactose- or glucose-monosaccharide-unit (Gal or Glc), C represents HexNac or Hex or is absent, n represents 1-50, V represents OH, a carbohydrate radical or a connecting point on a support T, with the proviso that if V represents OH, n represents 1, and if V represents a carbohydrate radical or a support T, n represents the number of carbohydrate unites of general formula (II) directly connected to said carbohydrate radical or support, X represents a sialic acid or a sialic acid derivative, wherein a second sialic acid or a sialic acid derivative or more sialic acid or sialic acid derivatives can be connected to an α2-8 bond, a phosphate, a sulphate, or carboxyl-group or a monosaccharide having a phosphate, sulphate, or carboxyl group and only one of the radicals X is present.

    摘要翻译: 本发明涉及含有至少一种通式(II)的碳水化合物单元的通式(I)的唾液酸碳水化合物用于免疫调节,免疫抑制和预防和治疗人和动物感染的用途。 在所述式(II)中,Sia表示α2-3键中的唾液酸或唾液酸衍生物,Gal表示半乳糖 - 单糖单元,HexNac表示N-乙酰化的半乳糖胺或葡糖胺单糖单元(GalNAc或GlcNAc ),Hex表示半乳糖或葡萄糖单糖单元(Gal或Glc),C表示HexNac或Hex或不存在,n表示1-50,V表示OH,碳水化合物基团或载体T上的连接点, 条件是如果V表示OH,n表示1,并且如果V表示碳水化合物基团或载体T,则n表示与所述碳水化合物基团或载体直接连接的通式(II)的碳水化合物单元的数目,X表示 唾液酸或唾液酸衍生物,其中第二唾液酸或唾液酸衍生物或更多的唾液酸或唾液酸衍生物可以连接到α2-8键,磷酸盐,硫酸盐或羧基或单糖上,其具有 磷酸盐,硫酸盐, 或羧基,并且仅存在基团X中的一个。